RESUMEN

We present a case of a 30-year-old man with relapsing-remitting multiple sclerosis who developed psoriasiform dermatitis following his second course of ocrelizumab. This resolved with topical therapies and discontinuation of treatment. Cases of psoriasiform rashes have been increasingly reported in the use of ocrelizumab and are possibly due to B-cell (CD20) depletion and T-cell overregulation. Nevertheless, skin-related adverse reactions are not yet considered in the risk management plans of anti-CD20 treatments in multiple sclerosis.

Asunto(s)

Anticuerpos Monoclonales Humanizados , Esclerosis Múltiple Recurrente-Remitente , Psoriasis , Humanos , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/efectos adversos , Masculino , Adulto , Psoriasis/tratamiento farmacológico , Psoriasis/inducido químicamente , Factores Inmunológicos/efectos adversos , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/patología